C. Guguen-guillouzo, I. Morel, and A. Guillouzo, Differential sensitivity of metabolically competent and non-competent HepaRG cells to apoptosis induced by diclofenac combined or not with TNF-?, Toxicol Lett, vol.58, pp.71-85, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01372855

C. Aninat, A. Piton, D. Glaise, L. Charpentier, T. Langouët et al., EXPRESSION OF CYTOCHROMES P450, CONJUGATING ENZYMES AND NUCLEAR RECEPTORS IN HUMAN HEPATOMA HepaRG CELLS, Drug Metabolism and Disposition, vol.34, issue.1, pp.75-83, 2006.
DOI : 10.1124/dmd.105.006759
URL : https://hal.archives-ouvertes.fr/hal-00702085

S. Anthérieu, P. Bachour-el-azzi, J. Dumont, Z. Abdel-razzak, C. Guguen-guillouzo et al., Oxidative stress plays a major role in chlorpromazine-induced cholestasis in human HepaRG cells, Hepatology, vol.35, issue.4, pp.1518-1529, 2013.
DOI : 10.1053/jhep.2002.31724

P. Bachour-el-azzi, A. Sharanek, A. Burban, R. Li, R. Guével et al., Comparative Localization and Functional Activity of the Main Hepatobiliary Transporters in HepaRG Cells and Primary Human Hepatocytes, Toxicological Sciences, vol.145, issue.1, pp.157-168, 2015.
DOI : 10.1093/toxsci/kfv041
URL : https://hal.archives-ouvertes.fr/hal-01134682

R. Barst, A review of pulmonary arterial hypertension: role of ambrisentan, Vasc Health Risk Manag, vol.3, pp.11-22, 2007.

O. Ben-yehuda, D. Pizzuti, A. Brown, M. Littman, H. Gillies et al., Long-Term Hepatic Safety of Ambrisentan in Patients With Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol.60, issue.1, pp.80-81, 2012.
DOI : 10.1016/j.jacc.2012.03.025

M. Bolli, C. Boss, C. Binkert, S. Buchmann, D. Bur et al., ???-propylsulfamide (Macitentan), an Orally Active, Potent Dual Endothelin Receptor Antagonist, Journal of Medicinal Chemistry, vol.55, issue.17, pp.7849-7861, 2012.
DOI : 10.1021/jm3009103

S. Bruderer, G. Hopfgartner, M. Seiberling, J. Wank, P. Sidharta et al., Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans, Xenobiotica, vol.37, issue.9, pp.901-910, 2012.
DOI : 10.1007/s00228-011-1043-2

M. Burbank, A. Burban, A. Sharanek, R. Weaver, C. Guguen-guillouzo et al., Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis, Drug Metabolism and Disposition, vol.44, issue.11, pp.1780-1793, 2016.
DOI : 10.1124/dmd.116.071373
URL : https://hal.archives-ouvertes.fr/hal-01398437

V. Cerec, D. Glaise, D. Garnier, S. Morosan, B. Turlin et al., Transdifferentiation of hepatocyte-like cells from the human hepatoma HepaRG cell line through bipotent progenitor, Hepatology, vol.103, issue.4, pp.957-967, 2007.
DOI : 10.1007/s004180100310
URL : https://hal.archives-ouvertes.fr/hal-00690471

M. Chaumais, C. Guignabert, L. Savale, X. Jaïs, A. Boucly et al., Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension, American Journal of Cardiovascular Drugs, vol.9, issue.1, pp.13-26, 2015.
DOI : 10.2165/11202270-000000000-00000

J. Croxtall and S. Keam, Ambrisentan, Drugs, vol.46, issue.3, pp.2195-2204, 2008.
DOI : 10.7326/0003-4819-115-5-343

D. Alonzo, G. Barst, R. Ayres, S. Bergofsky, E. Brundage et al., Survival in patients with primary pulmonary hypertension, 1991.

K. Fattinger, C. Funk, M. Pantze, C. Weber, J. Reichen et al., The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions, Clinical Pharmacology & Therapeutics, vol.69, issue.4, pp.223-231, 2001.
DOI : 10.1067/mcp.2001.114667

L. Fouassier, N. Kinnman, G. Lefèvre, E. Lasnier, C. Rey et al., Contribution of mrp2 in alterations of canalicular bile formation by the endothelin antagonist bosentan, Journal of Hepatology, vol.37, issue.2, pp.184-191, 2002.
DOI : 10.1016/S0168-8278(02)00107-1

Y. Fukumoto, N. Yamada, H. Matsubara, M. Mizoguchi, K. Uchino et al., Double-Blind, Placebo-Controlled Clinical Trial With a Rho-Kinase Inhibitor in Pulmonary Arterial Hypertension, Circulation Journal, vol.77, issue.10, pp.2619-2625, 2013.
DOI : 10.1253/circj.CJ-13-0443

N. Galiè, M. Hoeper, J. Gibbs, and G. Simonneau, Liver toxicity of sitaxentan in pulmonary arterial hypertension, European Respiratory Journal, vol.37, issue.2, pp.475-476, 2011.
DOI : 10.1183/09031936.00194810

J. Gatfield, C. Grandjean, T. Sasse, M. Clozel, and O. Nayler, Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells, PLoS ONE, vol.7, issue.10, p.47662, 2012.
DOI : 10.1371/journal.pone.0047662.t002
URL : http://doi.org/10.1371/journal.pone.0047662

P. Sidharta, P. Van-giersbergen, A. Halabi, and J. Dingemanse, Macitentan: entry-into-humans study with a new endothelin receptor antagonist, European Journal of Clinical Pharmacology, vol.29, issue.10, pp.977-984, 2011.
DOI : 10.1093/eurheartj/ehn234
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3169777

G. Simonneau, N. Galiè, P. Jansa, G. Meyer, H. Hiti et al., Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients, International Journal of Cardiology, vol.172, issue.2, 2014.
DOI : 10.1016/j.ijcard.2013.12.179

N. Sood, Macitentan for the treatment of pulmonary arterial hypertension, Expert Opinion on Pharmacotherapy, vol.60, issue.1, pp.2733-2739, 2014.
DOI : 10.1016/j.jacc.2012.03.025

F. Stavros, W. Kramer, and M. Wilkins, The effects of sitaxentan on sildenafil pharmacokinetics and pharmacodynamics in healthy subjects, British Journal of Clinical Pharmacology, vol.64, issue.1, pp.23-26, 2010.
DOI : 10.1111/j.1365-2125.2009.03541.x

S. Takatsuki, E. Rosenzweig, W. Zuckerman, D. Brady, M. Calderbank et al., Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension, Pediatric Pulmonology, vol.67, issue.1, pp.27-34, 2013.
DOI : 10.1111/j.1365-2125.2009.03384.x

A. Treiber, R. Schneiter, S. Hausler, and B. Stieger, Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil, Drug Metabolism and Disposition, vol.35, issue.8, pp.1400-1407, 2007.
DOI : 10.1124/dmd.106.013615

A. Velayati, M. Valerio, M. Shen, S. Tariq, G. Lanier et al., Update on pulmonary arterial hypertension pharmacotherapy, Postgraduate Medicine, vol.2012, issue.19, pp.460-473, 2016.
DOI : 10.1093/eurheartj/ehu035